ABT
Income statement / Annual
Last year (2024), Abbott Laboratories's total revenue was $41.95 B,
an increase of 4.59% from the previous year.
In 2024, Abbott Laboratories's net income was $13.40 B.
See Abbott Laboratories,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$41.95 B |
$40.11 B |
$43.65 B |
$43.08 B |
$34.61 B |
$31.90 B |
$30.58 B |
$27.39 B |
$20.85 B |
$20.41 B |
| Cost of Revenue |
$20.63 B
|
$20.07 B
|
$21.33 B
|
$19.86 B
|
$17.23 B
|
$15.21 B
|
$14.76 B
|
$14.32 B
|
$9.61 B
|
$9.45 B
|
| Gross Profit |
$21.33 B
|
$20.04 B
|
$22.32 B
|
$23.21 B
|
$17.38 B
|
$16.69 B
|
$15.82 B
|
$13.07 B
|
$11.24 B
|
$10.96 B
|
| Gross Profit Ratio |
0.51
|
0.5
|
0.51
|
0.54
|
0.5
|
0.52
|
0.52
|
0.48
|
0.54
|
0.54
|
| Research and Development Expenses |
$2.82 B
|
$2.72 B
|
$2.85 B
|
$2.74 B
|
$2.42 B
|
$2.41 B
|
$2.29 B
|
$2.13 B
|
$1.36 B
|
$1.37 B
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.74 B
|
$9.12 B
|
$6.67 B
|
$6.79 B
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.65 B
|
$10.88 B
|
$11.11 B
|
$11.28 B
|
$9.67 B
|
$9.69 B
|
$9.69 B
|
$8.96 B
|
$6.64 B
|
$6.64 B
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$14.47 B
|
$13.60 B
|
$13.96 B
|
$14.01 B
|
$12.09 B
|
$12.10 B
|
$11.98 B
|
$11.09 B
|
$8.00 B
|
$8.01 B
|
| Cost And Expenses |
$35.10 B
|
$33.67 B
|
$35.29 B
|
$33.88 B
|
$29.32 B
|
$27.31 B
|
$26.73 B
|
$25.42 B
|
$17.60 B
|
$17.46 B
|
| Interest Income |
$344.00 M
|
$385.00 M
|
$183.00 M
|
$43.00 M
|
$46.00 M
|
$94.00 M
|
$105.00 M
|
$124.00 M
|
$99.00 M
|
$105.00 M
|
| Interest Expense |
$603.00 M
|
$698.00 M
|
$315.00 M
|
$410.00 M
|
$708.00 M
|
$818.00 M
|
$729.00 M
|
$880.00 M
|
$304.00 M
|
$178.00 M
|
| Depreciation & Amortization |
$3.22 B
|
$3.24 B
|
$3.27 B
|
$3.54 B
|
$3.33 B
|
$3.01 B
|
$3.28 B
|
$3.02 B
|
$1.35 B
|
$1.47 B
|
| EBITDA |
$10.83 B |
$10.61 B |
$11.89 B |
$12.16 B |
$9.00 B |
$7.91 B |
$6.88 B |
$6.13 B |
$3.07 B |
$4.83 B |
| EBITDA Ratio |
0.26
|
0.26
|
0.27
|
0.28
|
0.26
|
0.25
|
0.22
|
0.22
|
0.15
|
0.24
|
| Operating Income Ratio |
0.16
|
0.16
|
0.19
|
0.21
|
0.15
|
0.14
|
0.13
|
0.07
|
0.16
|
0.14
|
| Total Other Income/Expenses Net |
$188.00 M
|
$229.00 M
|
-$56.00 M
|
-$989.00 M
|
-$323.00 M
|
-$514.00 M
|
-$971.00 M
|
$259.00 M
|
-$1.84 B
|
$234.00 M
|
| Income Before Tax |
$7.01 B
|
$6.66 B
|
$8.31 B
|
$8.21 B
|
$4.97 B
|
$4.08 B
|
$2.87 B
|
$2.23 B
|
$1.41 B
|
$3.18 B
|
| Income Before Tax Ratio |
0.17
|
0.17
|
0.19
|
0.19
|
0.14
|
0.13
|
0.09
|
0.08
|
0.07
|
0.16
|
| Income Tax Expense |
-$6.39 B
|
$941.00 M
|
$1.37 B
|
$1.14 B
|
$497.00 M
|
$390.00 M
|
$539.00 M
|
$1.88 B
|
$350.00 M
|
$577.00 M
|
| Net Income |
$13.40 B
|
$5.72 B
|
$6.93 B
|
$7.07 B
|
$4.50 B
|
$3.69 B
|
$2.37 B
|
$477.00 M
|
$1.40 B
|
$4.42 B
|
| Net Income Ratio |
0.32
|
0.14
|
0.16
|
0.16
|
0.13
|
0.12
|
0.08
|
0.02
|
0.07
|
0.22
|
| EPS |
7.67 |
3.3 |
3.94 |
3.97 |
2.52 |
2.07 |
1.35 |
0.27 |
0.95 |
3 |
| EPS Diluted |
7.64 |
3.27 |
3.91 |
3.94 |
2.5 |
2.06 |
1.34 |
0.27 |
0.94 |
2.94 |
| Weighted Average Shares Out |
$1.73 B
|
$1.73 B
|
$1.75 B
|
$1.78 B
|
$1.77 B
|
$1.77 B
|
$1.76 B
|
$1.74 B
|
$1.47 B
|
$1.47 B
|
| Weighted Average Shares Out Diluted |
$1.75 B
|
$1.75 B
|
$1.76 B
|
$1.79 B
|
$1.79 B
|
$1.78 B
|
$1.77 B
|
$1.75 B
|
$1.48 B
|
$1.51 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
